CuraSen Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10.9M

  • Investors
  • 10

CuraSen General Information

Description

Operator of a biopharmaceutical company intended for the development of novel treatments for neurodegenerative diseases. The company engages in developing small molecules that target innate homeostatic pathways and develops drugs for neurodegenerative disorders like inflammation, proteinopathy, neuronal atrophy, Alzheimer's, and Parkinson's diseases, enabling healthcare professionals to effectively treat patients with neurodegenerative diseases.

Contact Information

Website
www.curasen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650)

CuraSen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CuraSen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 24-Aug-2026 $10.9M Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 18-Sep-2024 Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private 01-Nov-2023 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 11-Oct-2023 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 21-Oct-2021 $18M $72.5M Completed Clinical Trials - Phase 1
1. Later Stage VC (Series A) 17-Oct-2018 $54.5M $54.5M Completed Pre-Clinical Trials
To view CuraSen’s complete valuation and funding history, request access »

CuraSen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A Prime
To view CuraSen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

CuraSen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended for the development of novel treatments for neurodegenerative diseases.
Drug Discovery
San Carlos, CA
20 As of 2025

Clarksville, MD
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CuraSen Competitors (19)

One of CuraSen’s 19 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD
Alzheon Venture Capital-Backed Framingham, MA
Neurogene Formerly VC-backed New York, NY
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
Alector Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 19 competitors. Get the full list »

CuraSen Patents

CuraSen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025188807-A1 Combination compositions and methods of use Pending 06-Mar-2024
WO-2025188807-A8 Combination compositions and methods of use Pending 06-Mar-2024
US-20260207568-A1 Compositions and methods for improving neurological diseases and disorders Pending 21-Dec-2022
WO-2024137506-A1 Compositions and methods for improving neurological diseases and disorders Inactive 21-Dec-2022
US-20260207533-A1 Methods for treating various conditions and indications with agonists and antagonists Pending 21-Dec-2022 A61K31/138
To view CuraSen’s complete patent history, request access »

CuraSen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CuraSen Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
ABRDN Emerging Markets Equity Income Asset Manager Minority
abrdn Healthcare Investors Hedge Fund Minority
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital Minority
Alta Partners Venture Capital Minority
Chiesi Ventures Corporate Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

CuraSen FAQs

  • When was CuraSen founded?

    CuraSen was founded in 2013.

  • Where is CuraSen headquartered?

    CuraSen is headquartered in San Carlos, CA.

  • What is the size of CuraSen?

    CuraSen has 20 total employees.

  • What industry is CuraSen in?

    CuraSen’s primary industry is Drug Discovery.

  • Is CuraSen a private or public company?

    CuraSen is a Private company.

  • What is CuraSen’s current revenue?

    The current revenue for CuraSen is .

  • How much funding has CuraSen raised over time?

    CuraSen has raised $107M.

  • Who are CuraSen’s investors?

    ABRDN Emerging Markets Equity Income, abrdn Healthcare Investors, Alzheimers Drug Discovery Foundation, Alta Partners, and Chiesi Ventures are 5 of 10 investors who have invested in CuraSen.

  • Who are CuraSen’s competitors?

    NeuroNascent, Alzheon, Neurogene, Neurona Therapeutics, and Alector are some of the 19 competitors of CuraSen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process